BrYet US Secures Patent for Nanoporous Silicon Drug Delivery Platform Targeting Cancer Treatment Resistance
Key Insights
BrYet US, Inc. (search) received U.S. Patent No. 12,390,420 for its targeted drug delivery technology using nanoporous silicon microparticles to overcome biological barriers in cancer (search) treatment.
The patented platform enables combination delivery of multiple kinase inhibitors (search) to the same tumor site, addressing treatment resistance through vertical and horizontal pathway inhibition.
The technology is designed for lung-selective delivery to minimize adverse side effects while enhancing therapeutic concentration at target sites.
BrYet US, Inc. (search) announced the expansion of its patent portfolio with the issuance of U.S. Patent No. 12,390,420, titled "Compositions for Targeted Delivery of Therapeutic Agents and Methods for the Synthesis and Use Thereof." The biotechnology company's newly patented technology addresses critical challenges in cancer (search) treatment by using proprietary nanoporous silicon microparticles (NSMP) to improve drug delivery and overcome treatment resistance.
Addressing Kinase Inhibitor Limitations
The patented technology specifically targets limitations associated with kinase inhibitors (search) (KIs), which are medicines designed to switch off overactive growth signals in cancers. Traditional kinase (search) inhibitor therapy faces significant challenges, including poor drug delivery to tumor sites and rapid development of drug resistance. The human body's biological barriers affect drug distribution and can prevent desired accumulation of therapeutic agents at cancer (search) sites while inducing adverse side effects.
BrYet's approach overcomes these barriers through a three-component platform comprising nanoporous silicon microparticles, functional groups introduced to the NSMP surface, and therapeutic drugs bound to the chemically modified NSMP through non-covalent interaction.
Combination Therapy Strategy
The platform enables packaging of multiple kinase inhibitors (search) together and releasing them at the same tumor site. This approach aims to address treatment resistance through vertical and horizontal pathway inhibition. According to the company, rational combinatorial targeted therapies have been shown to enhance antitumor activity and overcome resistance to therapy.
"This patent expands the applications for our targeted approach to treating cancer (search)," said Dr. Mauro Ferrari, President and CEO of BrYet US, Inc. (search) "It strengthens our ability to pair our delivery science with targeted medicines such as kinase inhibitors (search), bringing us one step closer to our ultimate goal of delivering functional cures."
Dr. Masakatsu Eguchi, Senior Scientist of BrYet US, Inc. (search) and the patent's inventor, explained the coordinated approach: "By coordinating how and where each agent is released, we aim to improve the odds against therapeutic resistance and help patients in the greatest need."
Clinical Development Progress
BrYet's delivery platform is designed to minimize adverse side effects through lung-selective delivery. The company recently received Australian approval to begin its first-in-human clinical study of ML-016, its lead therapeutic. ML-016 targets cancer (search)-specific phenotypes in lung and liver cancers using the same vascular-targeting NSMP technology that will be applied to the kinase (search) inhibitor programs.
The company plans to continue preclinical and clinical studies of its technology, including programs that combine targeted therapies such as kinase inhibitors (search), and explore partnerships to accelerate development toward clinical application.
Platform Technology Foundation
BrYet's approach is based on the belief that cancers localizing in the lungs and liver acquire molecular transport phenotypes that are conserved regardless of site of origin and largely independent of molecular mutations and their continued evolution. The company designs multi-component new chemical entities and formulations directed against fundamental aspects of these cancer (search)-associated, organ-specific transport phenotypes.
The company's proprietary platforms include mesoporous silicon components and mathematical formalism for designing multi-component drugs, termed Transport Oncophysics. BrYet believes similar approaches may provide advances against other forms of presently incurable cancers, as well as other pathologies of the lungs and liver.